# Tirzepatide: a dual GIP and GLP-1 receptor agonist

slug: tirzepatide · https://miscsubjects.com/a/tirzepatide · category: research · tags: peptide, tirzepatide, glp-1, gip, weight, obesity, sleep-apnoea · updated 2026-08-06T07:48:06.444Z

Tirzepatide is a once-weekly injection that acts on two gut-hormone receptors at once, and it has the strongest randomised human evidence of any compound documented on this site. The same opening should carry what it costs and what it does not settle: gut side effects hit most people during dose escalation, under 5% of participants stopped for them in the diabetes trial, and when the drug is withdrawn the weight comes back — the maintenance trial measured that directly, which is why it is on this page rather than left to a reader to discover. Across 2,539 adults in a 72-week trial, the top dose took 20.9% of body weight off, against 3.1% on placebo, and 57% of people on that dose lost a fifth of their body weight or more. In a second trial in 938 people who also had type 2 diabetes it took 14.7% off. In two more trials in people with obstructive sleep apnoea it cut breathing interruptions by 25 to 29 events an hour.

It is an approved prescription medicine, which changes what the numbers on this page mean: they belong to a specific manufactured product at a specific dose, not to the compound in the abstract. The site you are reading this on is funded by a business that sells this compound. That is a commercial interest, and it is why the placebo arm is quoted next to every result below.

## The molecule pulls two levers where the older drugs pull one

Your gut releases hormones when you eat. Two of them matter here. GLP-1 slows the stomach, tells the pancreas to release insulin when glucose is high, and signals fullness to the brain. GIP does related work on insulin and on how fat tissue handles energy.

Semaglutide copies GLP-1. Tirzepatide copies both — one molecule that fits both docking points. That is the whole design difference, and in head-to-head weight numbers the two-lever version comes out ahead.

It is a once-weekly injection under the skin. Doses run 2.5 mg to 15 mg, escalated slowly over about 20 weeks, because the side effects are worst while the dose is climbing.

## Twenty-point-nine per cent, and the four numbers that matter more than the headline

SURMOUNT-1 randomised 2,539 adults with a body mass index of 30 or more — or 27 or more with a weight-related problem — excluding diabetes, to 5 mg, 10 mg, 15 mg or placebo for 72 weeks. Average starting weight was 104.8 kg.

Weight change at week 72:

- 5 mg: −15.0%
- 10 mg: −19.5%
- 15 mg: −20.9%
- placebo: −3.1%

Those are averages, and averages hide the thing a person actually wants to know, which is their odds. The trial reported those too. Losing 5% or more of body weight: 85%, 89% and 91% across the three doses, against 35% on placebo. Losing 20% or more: 50% at 10 mg and 57% at 15 mg, against 3% on placebo.

Read the last pair again. More than half the people on the higher doses lost a fifth of their body weight. On placebo, three in a hundred did. There is no other compound documented on this site with a result of that shape.

Side effects were mostly stomach and bowel — nausea, diarrhoea, vomiting — mostly mild to moderate, and concentrated in the dose-climbing phase.

## The diabetes trial got a smaller number, and that is the expected pattern

SURMOUNT-2 ran the same design in 938 adults who had obesity and type 2 diabetes, at 10 mg and 15 mg for 72 weeks. Starting weight 100.7 kg, average HbA1c 8.02%.

Weight change at week 72: −12.8% at 10 mg, −14.7% at 15 mg, against −3.2% on placebo. Between 79% and 83% lost at least 5%, against 32% on placebo. Serious adverse events occurred in 7%; fewer than 5% stopped because of side effects.

Less weight comes off in people with diabetes than in people without it, on the same drug at the same dose. That holds across this drug class and it is worth knowing before comparing your own result to a headline from the wrong trial.

## Sleep apnoea is the second thing it was proven to change, and the effect is large

Two 52-week randomised trials in adults with moderate-to-severe obstructive sleep apnoea and obesity: one in people not using a CPAP machine, one in people using one. Average starting severity was about 50 breathing interruptions per hour of sleep — severe.

Breathing interruptions per hour at week 52 fell by 25.3 in the first trial and 29.3 in the second, against 5.3 and 5.5 on placebo. Every pre-specified secondary measure improved as well: weight, the oxygen debt built up overnight, C-reactive protein (an inflammation marker), systolic blood pressure, and how people rated their own sleep.

That second list matters as much as the breathing number. A drug approved on an apnoea endpoint that also moves blood pressure and an inflammation marker in the same trial is doing more than one thing, and all of it was measured under placebo control.

A 2026 post-hoc analysis of those same sleep trials went further and sorted participants by how they described themselves at the start — fatigued or not, sleepy or not, snoring or not, sleeping well or badly — then tracked both the machine measurements and what people said about their own days. That is the analysis worth reading for anyone whose complaint is exhaustion rather than a number on a sleep report, because it asks whether the people who felt worst got the most back.

## Stop taking it and the weight comes back: the trial that tested exactly that

SURMOUNT-MAINTAIN is the most useful trial for anybody deciding whether to start. Its 441 participants first lost weight on the maximum tolerated dose for 60 weeks. Then 378 of them were randomly assigned to one of three arms for another 52 weeks: stay on that dose, drop to 5 mg, or switch to placebo.

Weight change from baseline at week 112:

- Stayed on the maximum tolerated dose: −21.9%
- Dropped to 5 mg: −16.6%
- Switched to placebo: −9.9%

The placebo arm had already lost the weight. They put more than half of it back over a year without the drug. A dose reduction cost about a third of the result; stopping cost more than half.

That is what "chronic treatment" means in practice, and it is the part that gets left out of the marketing. The comparison to make is not this drug against nothing, it is this drug against this drug plus the plan for what happens when you stop.

## What the first few weeks predict about the rest

A 2026 post-hoc analysis pooled SURMOUNT-1 and SURMOUNT-2 and sorted participants by how much weight they had lost early, then followed what happened to each group: total weight change, cardiometabolic markers, tolerability and low-blood-sugar events.

The reason to know this exists: it means early response carries information. Somebody four weeks in, seeing very little movement, is not reading noise — that early trajectory tracks with where they land. It also cuts the other way. The people who respond fastest are not the ones who suffer most for it; tolerability did not simply worsen with a bigger response.

## The inflammation markers moved, separately from the weight

A 2026 analysis in the *Journal of the American College of Cardiology* took SURMOUNT-1 and looked at cardiovascular risk markers over the long haul rather than weight: high-sensitivity C-reactive protein, interleukin-6, fibrinogen and white-cell counts — the standard readouts of low-grade, whole-body inflammation.

Fat tissue is not inert. It releases signalling molecules that keep low-grade inflammation running throughout the body, and those four markers are how that state is read in a blood test. A trial showing them fall alongside 20% of body weight is measuring something separate from the weight itself.

What it is not measuring is any symptom. These are intermediate markers, they moved in the right direction in thousands of people under placebo control, and that is the whole claim.

## The rescue rule inside the maintenance trial, which is the detail that makes it honest

The maintenance trial did something most withdrawal studies do not: it wrote in an escape hatch. From week 84 — 24 weeks after the switch — any participant whose regain passed 50% of what they had lost could be given tirzepatide again as rescue. Of the 378 randomised, 345 (91%) completed.

That design choice matters twice over. Ethically, it means nobody was held in a placebo arm watching all of their result reverse. Statistically, it means the placebo arm's final figure of −9.9% is if anything generous to stopping: the people regaining fastest were pulled out and re-treated, and the analysis assumed they gained no further benefit from their assigned arm. The real cost of stopping is at least as large as the number printed.

## What the dose climb actually involves

The trials did not start people at the dose that produced the headline result. SURMOUNT-1 included a 20-week escalation period inside its 72 weeks, meaning more than a quarter of the trial was spent getting to the top dose. Doses run 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg.

Two consequences follow directly. The first is that the stomach and bowel side effects concentrate in that quarter of the timeline rather than spreading evenly, which is why the trials report them as mostly mild to moderate and mostly early. The second is that anyone comparing their own week-8 result to a 20.9% figure is comparing themselves to a 72-week endpoint reached at a dose they have not started yet.

## Population matters, and so does the setting

A 2026 systematic review and meta-analysis compared results in Asian against non-Asian adults with obesity and without diabetes across the phase 3 trials, because body composition and cardiometabolic risk differ between those groups at the same body mass index. The trials themselves were run across seven countries in the diabetes arm and included Chinese, Japanese, Russian, Brazilian and Argentine sites in the first — this is not a single-country evidence base.

There is also a five-year pragmatic trial running in UK primary care, SURMOUNT-REAL UK, enrolling roughly 3,000 adults with class I obesity, delivered as an addition to ordinary care and tracked through the health record rather than through clinic visits. That is the study that answers the question a trial never can: what happens when the drug is used by ordinary people in an ordinary practice, rather than by trial volunteers under supervision. It has not reported.

## The muscle question, which is real and unresolved

When people lose 20% of body weight, some of what leaves is muscle. That is true of dieting, of surgery, and of this drug class, and it is the one cost of a large weight loss that does not show up in the headline number.

The trials measured body weight, not body composition, as their main endpoint. Sub-studies using scans have reported that the proportion of loss coming from lean mass looks broadly similar to other weight-loss methods, which is reassurance rather than resolution.

What follows practically is not a hedge: resistance training and adequate protein during the loss phase are the standard countermeasures, and there is no version of this drug that removes the need for them.

## What is approved, what is compounded, and why the label on the vial matters

Tirzepatide is an FDA-approved medicine. It is sold as Mounjaro for type 2 diabetes and Zepbound for weight management and for obstructive sleep apnoea with obesity, both from Eli Lilly, both prescription-only.

Everything else in circulation is a different legal object. Compounded tirzepatide, "research use only" vials, and grey-market powder are not the approved product, have not been through the approval process, and carry no guarantee that the contents match the label. The trials on this page were run with the manufacturer's molecule at a controlled dose. A vial from another source has no established link to those numbers, and the correct assumption is that dose, purity and sterility are unknown until somebody tests them.

That distinction is sharper for this compound than for the others on this site, precisely because an approved version exists. With BPC-157 there is no approved product to compare against. Here there is, and buying around it means giving up the one thing the evidence is attached to.

## How the side effects actually behave

Across the trials the pattern is consistent. Nausea, vomiting, diarrhoea and constipation dominate, they cluster during dose escalation, most are mild to moderate, and discontinuation for side effects ran under 5% in the diabetes trial.

Two further points that come from the trial designs rather than the results. The 20-week escalation exists because going up faster produces worse symptoms — the slow ramp is part of the drug, not a suggestion. And gallbladder problems and pancreatitis appear as recognised risks across this whole class, uncommon but serious, which is a reason the approved product is prescription-only and supervised.

## Where this sits next to the other compounds on this site

Set the evidence side by side and the contrast is the point.

Tirzepatide: two 72-week randomised trials with 3,477 people between them, two 52-week trials in sleep apnoea, a 112-week maintenance trial, regulatory approval, and a defined dose.

BPC-157: no completed randomised trial in a person, a large animal literature, and a counted self-reported record.

TB-500: the molecule sold is not the molecule studied, and no human study has measured it.

That gap is not a reason to prefer one over another — they are aimed at different things and measured to different standards. It is a reason to be exact about which kind of claim you are relying on. Here, the claim is weight, and it is proven.

One more thing is worth stating plainly, because it is the difference between this page and most writing about this drug. Every figure above is a group average from a randomised comparison, which is the only kind of number that survives contact with a placebo. The 3.1% the placebo group lost in SURMOUNT-1 is what participation in a trial does on its own — the attention, the food diaries, the fortnightly weigh-ins. Any account of a weight-loss compound that does not carry its placebo number is not reporting a result, it is reporting an anecdote with a sample size. That is the reason a compound with 3,477 people in two trials sits on the same site as compounds whose whole record is forty posts, and the reason the two are never described in the same register here.

## What is still open on this compound

Three things are not settled by anything above. How long the effect holds beyond the two years these trials cover — the longest ran 112 weeks, and obesity is measured in decades. What the loss is made of in the long run, since body composition was a sub-study rather than a primary endpoint. And what happens in ordinary care rather than trial conditions, which is what the five-year pragmatic trial exists to answer and has not yet.

There is also a gap that no trial fixes. The evidence on this page belongs to a manufactured product given at a controlled dose under supervision. The further a vial sits from that description, the less of this page applies to it, and nothing in the literature tells you how much less.

Nine published trials and analyses are attached to this page. Every number above comes from one of them.


## Sources

1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — https://pubmed.ncbi.nlm.nih.gov/35658024/
2. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — https://pubmed.ncbi.nlm.nih.gov/37385275/
3. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) — https://pubmed.ncbi.nlm.nih.gov/38912654/
4. Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN) — https://pubmed.ncbi.nlm.nih.gov/42119587/
5. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses — https://pubmed.ncbi.nlm.nih.gov/42412744/
6. Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials — https://pubmed.ncbi.nlm.nih.gov/42348366/
7. Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis — https://pubmed.ncbi.nlm.nih.gov/42233927/
8. Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis — https://pubmed.ncbi.nlm.nih.gov/42487213/
9. SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity — https://pubmed.ncbi.nlm.nih.gov/42297568/


---

# Tesofensine produced the best weight-loss number of its era, and never became a medicine

slug: tesofensine · https://miscsubjects.com/a/tesofensine · category: compound · tags: tesofensine, obesity, appetite, monoamine reuptake, phase II · updated 2026-08-05T09:39:19.591Z

Tesofensine is a pill that was tested for weight loss, produced the largest result any obesity drug had produced at the time, and then did not become a medicine. Understanding why is most of what there is to know about it.

It was made by a Danish company, NeuroSearch, and it started life as something else entirely. Under the name NS2330 it was tried in Parkinson's disease and in Alzheimer's disease. It failed at both. What the trials did show was that people taking it lost weight, and lost it consistently enough that the company changed direction and tested it as an obesity drug.

## What it does inside the brain

Your brain passes messages between nerve cells using chemicals called neurotransmitters. A nerve cell releases a chemical into the tiny gap between itself and the next cell, the next cell reads it, and then the first cell pulls the chemical back in to be used again. That pulling-back is called reuptake, and the molecular machinery that does it is called a transporter. Block the transporter and the chemical stays in the gap longer, so the message keeps being read.

Tesofensine blocks three transporters at once: the ones for noradrenaline, dopamine and serotonin. That is what "triple monoamine reuptake inhibitor" means, and it is the whole mechanism. The three chemicals it acts on are the three most closely tied to appetite, alertness and reward. Serotonin is involved in feeling full. Noradrenaline drives arousal and raises the rate at which the body burns energy. Dopamine carries the signal that something is worth wanting, which is why it matters for food specifically and not just for hunger.

Most appetite drugs push on one of these. Tesofensine pushes on all three. The published trial describes it exactly this way — "an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin" — and that breadth is the reason the effect was large, and also the reason the side effects were what they were. You cannot raise all three of these chemicals across the brain and only change eating.

## What actually happened in the trial

The trial that made tesofensine's reputation ran in five Danish obesity clinics and published in *The Lancet* in November 2008. It was a phase II study: 203 people with a body mass index between 30 and 40, all put on a reduced-calorie diet, then randomly assigned to one of three doses of tesofensine or to a placebo, once daily for 24 weeks. Neither the patients nor the doctors knew who was getting what. 161 people, or 79 percent, finished.

The results, in the paper's own words:

> "After 24 weeks, the mean weight loss produced by diet and placebo was 2.0% (SE 0.60). Tesofensine 0.25 mg, 0.5 mg, and 1.0 mg and diet induced a mean weight loss of 4.5% (0.87), 9.2% (0.91), and 10.6% (0.84), respectively, greater than diet and placebo (p<0.0001)."

Read those numbers carefully, because they are routinely misquoted. The 9.2 percent at the 0.5 mg dose is weight loss *greater than* the placebo group, not total weight loss. Placebo plus diet took off 2.0 percent. So the 0.5 mg group came in around 11 percent below where they started, and the drug's own contribution was the 9.2.

For 2008 that was a very large number. The paper opens by saying why it mattered: "Weight-loss drugs produce an additional mean weight loss of only 3-5 kg above that of diet and placebo over 6 months, and more effective pharmacotherapy of obesity is needed." Against a 3–5 kg benchmark, tesofensine at 0.5 mg roughly doubled it. The authors said so, and hedged it in the same sentence: "Our results suggest that tesofensine 0.5 mg might have the potential to produce a weight loss twice that of currently approved drugs. However, these findings of efficacy and safety need confirmation in phase III trials."

That confirmation never arrived.

## The part that is usually left out

In April 2013, *The Lancet* published an expression of concern about that trial.

An expression of concern is a formal notice from a journal that something about a published paper is under question and readers should treat it with caution. It is not a retraction — the paper stands — but it is not nothing either, and it is attached to the record permanently. The notice is indexed in PubMed under its own identifier, PMID 23561987, and its title is simply "Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial." The PubMed record for the 2008 paper carries the link both ways.

This matters more for tesofensine than it would for most compounds, because the 2008 trial is not one piece of evidence among many. It is essentially the whole human efficacy case. The 9.2 percent figure that appears on every page selling this compound comes from that single 203-person phase II study, and that study has a journal-issued caution attached to it. A page that quotes the number and omits the notice has told you the good half of the record.

## What a second, smaller study showed about the mechanism

A separate trial, published in the *International Journal of Obesity* in 2010, went looking for *how* the weight came off. Thirty-two overweight and moderately obese men took 2.0 mg daily for a week, then 1.0 mg daily for a second week, or placebo, while being told to keep their eating and activity the same. They were measured inside a respiration chamber, which is a sealed room that can account for every calorie a body burns.

Two things came out of it. Appetite changed a great deal: the paper reports that tesofensine "induced higher ratings of satiety and fullness and concomitantly lower prospective food intake than placebo." Energy expenditure barely changed: "No significant effect of TE on total 24-h EE could be demonstrated compared with PL, but higher energy expenditure was observed during the night period (4.6%; P<0.05) when adjusted for changes in body composition." Fat burning did shift, by 18 grams over 24 hours.

The honest reading is that tesofensine works mostly by making people want to eat less, not by meaningfully raising the rate at which they burn energy. That is worth knowing, because "boosts metabolism" is the claim most often made for it, and the one study designed to measure exactly that found the effect small and confined to the night.

## Side effects, and the one that ended it

The 2008 trial lists them plainly: "The most common adverse events caused by tesofensine were dry mouth, nausea, constipation, hard stools, diarrhoea, and insomnia." Dry mouth and insomnia are the signature of a drug raising noradrenaline. They are not incidental; they are the mechanism showing up where it was not wanted.

The cardiovascular numbers are where the programme ran into trouble. At 0.25 mg and 0.5 mg there was "no significant increases in systolic or diastolic blood pressure compared with placebo," but heart rate was another matter: "heart rate was increased by 7.4 beats per min in the tesofensine 0.5 mg group (p=0.0001)." At the 1.0 mg dose, blood pressure rose as well.

Seven and a half extra beats a minute, every minute, in a population that already carries cardiovascular risk from obesity, is the kind of finding a regulator weighs against the benefit. The history of appetite drugs is largely a history of exactly this trade — sibutramine, which also raised heart rate and blood pressure through noradrenaline and serotonin reuptake inhibition, was withdrawn from the American and European markets in 2010 after a long cardiovascular outcomes trial found more heart attacks and strokes in the drug group. Tesofensine belongs to the same pharmacological family, and it was being developed into a regulatory climate shaped by that withdrawal.

## How it moves through the body

Tesofensine has an unusually long half-life for a small molecule of its type — on the order of 200 to 230 hours, which is eight to ten days. Half-life is the time it takes for the amount in your blood to fall by half. Ten days is very long. Fluoxetine, famous for lingering, is one to four days for the parent drug.

Two consequences follow, and both are practical rather than theoretical.

The first is that the drug accumulates for weeks. With a ten-day half-life it takes roughly five half-lives — about six or seven weeks — before the amount in your blood stops climbing and settles at a steady level. The dose you take on day one and the dose you take on day fifty are the same dose, but the amount circulating in your body on day fifty is several times higher. This is why side effects on a compound like this often appear well after starting, and why they appear without anything having changed. Nothing changed. The accumulation caught up.

The second is that stopping does not stop it. If you take the last dose today, meaningful amounts are still present a month from now. That cuts both ways: there is no withdrawal cliff, but there is also no fast exit if something goes wrong. If your heart rate has climbed and you want it back down, you wait weeks, not hours. Anything that pushes on noradrenaline — a stimulant, a decongestant, a strong dose of caffeine — is stacking onto a drug that has not left, and will not for some time.

It is taken by mouth and it is a small molecule, not a peptide, which is worth stating because it is sold alongside peptides and constantly described as one. Peptides are short chains of amino acids and mostly have to be injected because the gut digests them. Tesofensine is neither a peptide nor injected. If a supplier lists it as a peptide, they are describing their catalogue rather than the compound.

## Where it stands now

Tesofensine is not an approved medicine in the United States, the United Kingdom or the European Union. It has no FDA approval for any indication. The compound was later licensed to Saniona, which has pursued it for hypothalamic obesity — a specific, rare condition in which damage to the hypothalamus, usually from a brain tumour or its treatment, destroys the body's ability to regulate appetite at all. That is a different and much narrower target than general obesity, and pursuing it is a reasonable read of what the compound can support.

Meanwhile the landscape it was competing in changed completely. The GLP-1 drugs — semaglutide, tirzepatide — now produce 15 to 22 percent total body weight loss in phase III trials with tens of thousands of participants and cardiovascular outcome data. A phase II result of 9.2 percent above placebo in 203 people, with an expression of concern attached, is no longer a competitive position. That is the honest reason tesofensine is a research compound in 2026 and not a prescription.

## What that means if you are looking at it

Everything below is what the record does and does not support. None of it is medical advice, and tesofensine is sold for research use only, not for human consumption.

The dosing you will see quoted — 0.25 mg to 1.0 mg once daily — comes from the 2008 trial and nowhere else. There is no long-term human safety data at any dose. The longest controlled human exposure in the published literature is 24 weeks.

Three things are genuinely unknown, and no amount of reading will resolve them, because the studies were not done. Nobody knows what happens after 24 weeks. Nobody knows whether the heart rate increase translates into cardiovascular events over years, which is the exact question that ended sibutramine and required a 10,000-patient trial to answer. And nobody knows whether the 2008 numbers would replicate, which is what phase III exists to establish and what the expression of concern makes a live question rather than a formality.

What is known is narrower and firmer. It reduces appetite, substantially, in people who take it. It raises resting heart rate at doses that produce meaningful weight loss. It causes dry mouth and insomnia often enough that both appear in the trial's own list. It works through three transporters simultaneously, which is why the appetite effect is large and why the side effects are systemic rather than local. And its single supporting trial carries a journal-issued caution that is part of the record whether or not the page you read it on mentions it.

Anyone taking a compound that raises heart rate by seven beats a minute should know their own resting heart rate and blood pressure before and during, and should know that the drug most similar to this one was pulled from two major markets over cardiovascular outcomes. That is not a scare; it is the specific, documented reason this compound is where it is.

## The interactions that are not optional to know about

Three of these are serious enough that they are worth stating on their own, separately from the general side effect list, because they are the ones with a named mechanism rather than a general caution.

Anything else that raises serotonin. Tesofensine blocks serotonin reuptake. So do the SSRI antidepressants — sertraline, fluoxetine, escitalopram and the rest — and so do the SNRIs, tramadol, triptans for migraine, St John's wort, and MDMA. Stacking two serotonin-raising drugs risks serotonin syndrome, which is not a subtle condition: agitation, a racing heart, high temperature, muscle rigidity, tremor, and in severe cases it is fatal. The ten-day half-life makes this worse rather than better, because "I stopped taking it" does not mean it is gone.

MAO inhibitors. These are an older class of antidepressant, and also include the Parkinson's drugs selegiline and rasagiline and the antibiotic linezolid. Combining an MAO inhibitor with a triple reuptake inhibitor is the textbook recipe for both serotonin syndrome and a hypertensive crisis, because one drug stops the breakdown of these chemicals while the other stops their removal from the synapse. This combination is contraindicated with every drug in tesofensine's family, and the required washout is measured in weeks in both directions.

Stimulants and anything that raises blood pressure. Amphetamines, methylphenidate, cocaine, high-dose caffeine, pseudoephedrine and phenylephrine in cold medicine, and most pre-workout formulas all push noradrenaline in the same direction tesofensine already is. The 2008 trial found 7.4 extra beats per minute at 0.5 mg from tesofensine alone. Adding a stimulant on top of that is adding to a number that was already the programme's main safety concern.

There is a fourth worth naming because it is easy to miss: anything that acts on dopamine. Tesofensine came out of Parkinson's research precisely because it raises dopamine, and dopamine-raising drugs can trigger or worsen psychosis in people predisposed to it, and can drive compulsive behaviour — gambling, shopping, eating — which is a well-documented effect of dopamine agonists in Parkinson's patients.

## What a page selling this will not tell you

Five things, all checkable, all missing from most of what is written about this compound.

The 9.2 percent is above placebo, not total. Placebo plus diet was 2.0 percent. The number quoted as the headline result is the difference, and the difference is the correct thing to quote — but it is quoted as if it were the total, which makes the drug sound better than the trial found.

There is one efficacy trial. Not a body of literature — one 203-person phase II study, published in 2008, plus a 32-person mechanism study in 2010 that was not designed to measure weight loss. Everything else is commentary on those two.

That trial has an expression of concern attached to it. Lancet 2013;381(9873):1167, PMID 23561987, linked from the PubMed record of the original in both directions.

Phase III never happened. The 2008 authors said in the paper that phase III confirmation was needed. There is no published phase III obesity trial. A drug that stops at phase II has not been shown to work in the sense the word usually means.

It failed in the two diseases it was built for. Parkinson's and Alzheimer's, under the name NS2330. The weight loss was originally a side effect, noticed in trials that were looking for something else and did not find it.

None of that makes it an uninteresting compound. It makes it a phase II compound with a real, measured appetite effect, a real, measured cardiovascular signal, a single supporting trial under formal caution, and a mechanism whose closest approved relative was withdrawn on cardiovascular grounds. That is a specific position, and it is a more useful thing to know than a percentage.


## Sources

1. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial — https://pubmed.ncbi.nlm.nih.gov/18950853/
2. Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial — https://pubmed.ncbi.nlm.nih.gov/23561987/
3. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial — https://pubmed.ncbi.nlm.nih.gov/18950853/
4. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men — https://pubmed.ncbi.nlm.nih.gov/20479765/
5. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men — https://pubmed.ncbi.nlm.nih.gov/20479765/
6. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial — https://pubmed.ncbi.nlm.nih.gov/18950853/
7. [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication] — https://pubmed.ncbi.nlm.nih.gov/19824222/


---

# Retatrutide: the third receptor, and what the evidence now establishes

slug: retatrutide · https://miscsubjects.com/a/retatrutide · tags: peptide, retatrutide, glp-1, obesity, disc · updated 2026-08-05T02:14:48.127Z

Retatrutide is one molecule that switches on three different hormone receptors at once: GLP-1, GIP, and glucagon. Semaglutide hits one of those. Tirzepatide hits two. Retatrutide adds the third, and that third one is the interesting part, because glucagon is the hormone most people know as the one that raises blood sugar — the opposite of what a diabetes drug is supposed to do.

Understanding why adding it works is most of understanding this drug.

**Where the evidence stands, before anything else.** Retatrutide has been tested in people. Phase 2 randomised trials in obesity and in type 2 diabetes are published, and the first phase 3 trial — a double-blind randomised trial in type 2 diabetes — has now reported. The obesity phase 3 trials and the cardiovascular and kidney outcome trials are still running. It is not an approved medicine in any country, so nothing sold under this name is the material that was studied.

## Why putting glucagon into a weight-loss drug is not a mistake

Glucagon does raise blood sugar. It also does something else: it increases energy expenditure. It tells the liver to break down stored fat and it raises the rate at which the body burns energy at rest.

So a molecule that activates the glucagon receptor on its own would burn more energy and worsen blood sugar. A molecule that activates GLP-1 and GIP lowers blood sugar strongly and reduces appetite. Put all three on one peptide and the GLP-1 and GIP arms more than cover the blood sugar cost of the glucagon arm, and you keep the extra energy expenditure.

The result is a drug that attacks weight from both sides at once — appetite down and energy out up — rather than appetite alone. Every other drug in this class works mainly on the intake side.

The elegance of that design has been demonstrated in an unusual way. Researchers testing the components in mice engineered to have no working GLP-1 receptor at all found that retatrutide still normalised body weight in those animals.

[[embed:source:s11]]

That is a mechanistic result rather than a clinical one, and it matters because it isolates the contribution of the other two arms. The weight effect is not simply a stronger version of what GLP-1 drugs do.

## What it actually does to weight, in numbers

The comparison that puts it in context is a network analysis of the drugs acting on the glucagon receptor, which ranks them against placebo on weight.

[[embed:source:s12]]

Retatrutide produced the greatest weight reduction of the class — a mean difference of 13.44 kg against placebo, ahead of survodutide at 10.74 kg, with cotadutide's effect small and not statistically significant.

The same analysis found retatrutide had the largest effect on HbA1c, the three-month average blood sugar measure — and it was the only one of the four whose effect on HbA1c reached statistical significance.

In the type 2 diabetes programme the blood sugar numbers are striking on their own terms: HbA1c improved by 2.2%, and 82% of participants reached 6.5% or below — a threshold at which many people would no longer meet the diagnostic criteria for diabetes.

[[embed:source:s13]]

The same summary reports improvements across blood pressure, lipids, waist circumference, and an 82% reduction in liver fat.

## The body composition question, answered directly

The standard objection to very effective weight-loss drugs is that a large fraction of what is lost is muscle rather than fat. It is a serious objection, particularly in older people, and the more weight a drug takes off the more it matters.

A substudy measured body composition directly rather than inferring it.

[[embed:source:s14]]

Fat mass fell 26.1% on the 8 mg dose and 23.2% on 12 mg, against 2.6% on placebo. And on the question people actually want answered:

[[embed:source:s15]]

The proportion of the loss that was lean mass was similar to other obesity treatments. Retatrutide takes off more total weight, and it does not appear to take off a disproportionate share of muscle in doing so.

Two honest caveats. The study was funded by the manufacturer, which is normal at this stage and worth stating. And 85% of the participants were White, which limits how confidently the result generalises.

## The liver finding, and why it is arguably the most important one

An 82% reduction in liver fat is a large number in a field where liver fat has been hard to move. Fatty liver disease has almost no approved drug treatment; a 2026 review notes that only two agents are specifically approved for it, and places retatrutide among the pipeline drugs showing marked reductions in liver fat and early signals of benefit in the more advanced inflammatory form.

[[embed:source:s16]]

Another 2026 review of the same area places it alongside the other multi-receptor drugs and is careful about the limits.

[[embed:source:s17]]

Early clinical data indicating potent effects. Evidence on whether it changes scarring in the liver remains limited. That distinction — reducing fat in the liver versus changing the disease that fat drives — is the one that will decide whether this becomes a liver drug or a weight drug with a liver side effect.

## What it feels like to take, from the people who took it

A substudy asked participants in the diabetes trial about hunger and eating rather than only weighing them.

[[embed:source:s18]]

People on the higher doses reported being less likely to feel hungry or to overeat, and — the more interesting finding — the people who lost the most weight were the same people who reported the largest changes in hunger and overeating.

That correlation is worth holding onto for a practical reason. If your appetite has not changed on a drug in this class, the weight is less likely to follow, and that is information available within weeks rather than months.

## What "three receptors on one molecule" actually required

It is worth understanding why this took until now, because it explains why the class looks the way it does and what the constraints are.

GLP-1, GIP and glucagon are structurally related hormones — close enough that a single engineered peptide can be made to fit all three receptors, and far enough apart that fitting all three well is difficult. The design problem is not simply binding all three. It is binding them in the right *ratio*.

Too much glucagon activity relative to the other two and blood sugar rises. Too little and the extra energy expenditure that justifies including it disappears. Too much GLP-1 activity relative to the rest and the gastrointestinal effects become intolerable before the target dose is reached. The molecule has to be balanced, and the balance is a property of the peptide sequence and its fatty-acid modification, not something a prescriber can adjust.

That has a practical consequence people miss. With a single-receptor drug, dose is the only variable and more is more. With a three-receptor drug, the ratio between the three effects is fixed at the point of manufacture, and only the total is dose-dependent. It also means a peptide with the wrong sequence is not a weaker version of the drug — it is a different drug with a different balance, and its blood sugar effect could point the other way.

A 2026 review of the wider field places these engineered multi-agonists in context: they work by mimicking the several-hormone response the body produces after bariatric surgery, rather than by amplifying one signal.

[[embed:source:s23]]

That framing explains the size of the effects better than "a stronger GLP-1 drug" does. The comparison to surgery is not only about how much weight comes off; it is about which mechanism is being copied.

## Who this class does not suit, and the practical constraints

Some of what follows is class knowledge from the approved drugs rather than retatrutide-specific evidence, and it is labelled as such because the distinction matters.

**Anyone with a history of medullary thyroid carcinoma or the endocrine syndrome associated with it** is excluded from GLP-1 drugs on the basis of rodent findings. That exclusion is applied to the class.

**Gastroparesis and significant gastrointestinal disease** sit badly with drugs whose main mechanism includes slowing stomach emptying.

**Pregnancy** is a contraindication across the class, and the appetite mechanism means people using these drugs while trying to conceive need a conversation about timing rather than an assumption.

**Anyone on insulin or a sulfonylurea** faces a real interaction: as the drug improves blood sugar, existing medication that lowers it further can cause hypoglycaemia. This is managed by adjusting the other drugs, which requires somebody monitoring.

The last point is the one that connects back to the glucagon arm. Retatrutide's blood sugar effect is the *net* of three receptor effects, two lowering and one raising. The trials established that net in specific populations on specific background medications. That is not a constant of nature; it is a measured result in a defined group.

## The side effects, and the class risk worth naming

Gastrointestinal symptoms are the commonest problem — nausea, vomiting, diarrhoea, constipation — and they are the reason the dose is escalated slowly rather than started at target. In the phase 2 programme they were the main adverse events reported, with no major safety concerns identified.

[[embed:source:s19]]

"No major safety concerns in phase 2" is a real statement and a limited one. Phase 2 trials enrol hundreds of people for months. Rare harms and long-term harms are what phase 3 and post-marketing surveillance are for, and only the first of those has begun to report.

One class-level risk deserves naming because it is asked about constantly. A meta-analysis of GLP-1 receptor agonists found a slightly increased risk of pancreatitis, and no significant association with pancreatic cancer overall.

[[embed:source:s20]]

Note that this is a finding about the established GLP-1 drugs, not about retatrutide specifically. Applying it here is a reasonable inference from a shared mechanism, not a measurement.

There is also a mechanistic reason to watch blood sugar more carefully with this drug than with its predecessors. The glucagon arm raises blood sugar. In the trials the other two arms more than compensate. In someone whose situation differs from the trial population — different medications, different insulin reserve — that balance is an assumption rather than a measurement.

## Where it is in development, stated plainly

**Retatrutide is not an approved medicine anywhere.** That is the fact that governs everything below, and it is true despite the programme having moved past phase 2.

The first phase 3 result has published. TRANSCEND-T2D-1 was a double-blind randomised phase 3 trial in people with type 2 diabetes whose blood sugar was not controlled by diet and exercise alone, with change in HbA1c at week 40 as its primary endpoint.

[[embed:source:s1]]

Retention was high — 91% of participants completed the treatment period on the study drug and 94% completed the study, which for a drug whose main side effects are gastrointestinal is itself a tolerability finding.

[[embed:source:s24]]

The rest of the programme is still running: the obesity phase 3 trials, and the cardiovascular and kidney outcome trials.

[[embed:source:s21]]

That last part — cardiovascular and renal outcome trials — is not a formality. For drugs in this class, outcome trials are how the field learns whether the metabolic improvements translate into fewer heart attacks and less kidney failure, and the answer has not always followed the surrogate measures.

Phase 2 results of this size attract language that outruns the evidence. One 2026 perspective describes the weight reductions as comparable to bariatric surgery and calls the drug a watershed.

[[embed:source:s22]]

That may prove right. It was also written from phase 2 data, and the distance between "unprecedented in phase 2" and "approved and durable in practice" is where a great many promising drugs have stopped. The first phase 3 result is now in, in diabetes; the weight-loss phase 3 results and the outcome trials are not.

## What this means for anything sold under this name

This is the part that matters most to anyone reading this page with a purchase in mind.

Because retatrutide is not approved, nothing sold under that name is a licensed medicine. There is no pharmacy supply chain, no regulator checking identity or purity, and no manufacturer standing behind what is in the vial. The dosing that produced the results above came from a controlled programme with slow escalation and monitoring — and dose escalation exists in these trials precisely because starting at target dose causes the gastrointestinal effects that make people stop.

The honest position: the trial results are real, they are large, and they were produced under conditions that have almost nothing in common with obtaining an unapproved peptide and self-administering it. The operator of this site has a commercial interest in compounds of this kind, which is exactly why that sentence appears here rather than at the bottom in small type.

## Ten people, and what the evidence supports about them

Ten people with obesity take retatrutide at the higher doses in a trial setting. On the pooled evidence, they lose substantially more weight than they would on any other drug in this class, and the proportion of that loss which is muscle is no worse than with the alternatives. Most of them experience gastrointestinal side effects at some point, particularly while the dose is being raised. Those who report the biggest change in hunger are the same ones who lose the most weight. Their liver fat falls substantially. Their blood pressure, lipids and waist measurement improve. Whether any of that translates into fewer cardiovascular events over years is being tested now and is not yet known for any of them.

## What the trials do not tell you

Four gaps are worth naming precisely, because they are the questions people ask and the literature does not yet answer.

**What happens when you stop.** No published retatrutide data addresses this. For the approved drugs in the class, stopping is followed by substantial weight regain, which is what you would expect from a drug whose mechanism is suppressing appetite while it is present. There is no reason to assume this molecule behaves differently, and no evidence that it does. Anyone planning to take it should plan for what follows.

**Whether the effects last.** The phase 2 results run to 48 weeks. Weight loss curves in this class typically flatten as the body adjusts, and where that plateau sits for retatrutide over two or three years is unknown.

**Whether the metabolic gains become clinical ones.** The published phase 3 trial measured HbA1c, not heart attacks. Lower blood sugar, lower blood pressure, better lipids and less liver fat are surrogates. They are strongly associated with fewer heart attacks and less kidney failure, and drugs that improve surrogates have sometimes failed to improve outcomes. That is precisely what the running outcome trials exist to settle.

**Who it works badly for.** With 85% White participants in the body composition substudy and a trial population selected by trial criteria, the honest answer about how this performs across different populations is that it has not been measured properly yet.

Those four are not criticisms of the drug. They are the difference between a phase 2 result and a medicine.

## Where this sits against the others

Against semaglutide and tirzepatide, retatrutide's case is the third receptor and the energy-expenditure arm it brings. Against bariatric surgery, the comparison people keep reaching for, the honest version is that phase 2 weight reductions are in a comparable range while durability, complication profile and decade-scale outcomes are not comparable at all, because one of them has decades of follow-up and the other has none.

The most defensible summary available today: the largest weight effect measured in its class, the largest blood sugar effect in its class, a substantial liver fat effect, an ordinary side-effect profile for the class, no unexpected safety signal so far, one published phase 3 trial in type 2 diabetes with high completion rates, and no approval anywhere.

## The seven things this evidence supports

1. **The third receptor is the whole story.** Glucagon adds energy expenditure to appetite suppression, and the other two arms cover its effect on blood sugar.
2. **The weight effect is the largest in its class, and it is measured against placebo.** 13.44 kg mean difference, ahead of every comparator in the network analysis.
3. **The muscle question has been answered directly, not argued.** Fat mass down 26.1% at 8 mg, with the lean mass proportion similar to other treatments in the class.
4. **The liver result may matter more than the weight result.** An 82% reduction in liver fat, in a disease with almost no approved treatment — and no evidence yet on scarring.
5. **If your appetite does not change, watch closely.** The people with the largest changes in hunger were the ones who lost the most weight.
6. **It is not an approved drug.** One phase 3 trial has reported, in diabetes. The obesity phase 3 trials and the cardiovascular and kidney outcome trials have not.
7. **Nothing sold under this name is the drug that was studied.** The results came from a monitored programme with controlled escalation and verified material. That is not what an unapproved peptide purchase is.


## Sources

1. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial — https://pubmed.ncbi.nlm.nih.gov/42250575/
2. Efficacy and safety of retatrutide for the treatment of obesity — https://pubmed.ncbi.nlm.nih.gov/40728138/
3. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis — https://pubmed.ncbi.nlm.nih.gov/39817343/
4. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis — https://pubmed.ncbi.nlm.nih.gov/40291085/
5. Retatrutide-A Game Changer in Obesity Pharmacotherapy — https://pubmed.ncbi.nlm.nih.gov/40563436/
6. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — https://pubmed.ncbi.nlm.nih.gov/40609566/
7. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) — https://clinicaltrials.gov/study/NCT05882045
8. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials — https://pubmed.ncbi.nlm.nih.gov/41090431/
9. A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes — https://clinicaltrials.gov/study/NCT05936151
10. A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8) — https://clinicaltrials.gov/study/NCT07232719
11. GIPR:GCGR co-agonism restores normal weight in obese rodents — https://pubmed.ncbi.nlm.nih.gov/41997446/
12. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials — https://pubmed.ncbi.nlm.nih.gov/41787737/
13. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
14. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — https://pubmed.ncbi.nlm.nih.gov/40609566/
15. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial — https://pubmed.ncbi.nlm.nih.gov/40609566/
16. Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes — https://pubmed.ncbi.nlm.nih.gov/41831086/
17. Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression — https://pubmed.ncbi.nlm.nih.gov/42195239/
18. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study — https://pubmed.ncbi.nlm.nih.gov/40916752/
19. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
20. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials — https://pubmed.ncbi.nlm.nih.gov/40988099/
21. Triple Agonism Based Therapies for Obesity — https://pubmed.ncbi.nlm.nih.gov/40741227/
22. The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities — https://pubmed.ncbi.nlm.nih.gov/41545327/
23. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders — https://pubmed.ncbi.nlm.nih.gov/41297910/
24. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial — https://pubmed.ncbi.nlm.nih.gov/42250575/